Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias - PubMed (original) (raw)
. 1995 Nov 23;378(6555):403-6.
doi: 10.1038/378403a0.
Affiliations
- PMID: 7477379
- DOI: 10.1038/378403a0
Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias
Y Trottier et al. Nature. 1995.
Abstract
A polyglutamine expansion (encoded by a CAG repeat) in specific proteins causes neurodegeneration in Huntington's disease (HD) and four other disorders, by an unknown mechanism thought to involve gain of function or toxicity of the mutated protein. The pathological threshold is 37-40 glutamines in three of these diseases, whereas the corresponding normal proteins contain polymorphic repeats of up to about 35 glutamines. The age of onset of clinical manifestations is inversely correlated to the length of the polyglutamine expansion. Here we report the characterization of a monoclonal antibody that selectively recognizes polyglutamine expansion in the proteins implicated in HD and in spinocerebellar ataxia (SCA) 1 and 3. The intensity of signal depends on the length of the polyglutamine expansion, and the antibody also detects specific pathological proteins expected to contain such expansion, in SCA2 and in autosomal dominant cerebellar ataxia with retinal degeneration, whose genes have not yet been identified.
Similar articles
- Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC, Faber PW, Persichetti F, Mittal V, Vonsattel JP, MacDonald ME, Gusella JF. Huang CC, et al. Somat Cell Mol Genet. 1998 Jul;24(4):217-33. doi: 10.1023/b:scam.0000007124.19463.e5. Somat Cell Mol Genet. 1998. PMID: 10410676 - Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease.
Truant R, Atwal RS, Burtnik A. Truant R, et al. Prog Neurobiol. 2007 Nov;83(4):211-27. doi: 10.1016/j.pneurobio.2006.11.004. Epub 2007 Jan 22. Prog Neurobiol. 2007. PMID: 17240517 Review. - Targeting several CAG expansion diseases by a single antisense oligonucleotide.
Evers MM, Pepers BA, van Deutekom JC, Mulders SA, den Dunnen JT, Aartsma-Rus A, van Ommen GJ, van Roon-Mom WM. Evers MM, et al. PLoS One. 2011;6(9):e24308. doi: 10.1371/journal.pone.0024308. Epub 2011 Sep 1. PLoS One. 2011. PMID: 21909428 Free PMC article. - Huntingtin-protein interactions and the pathogenesis of Huntington's disease.
Li SH, Li XJ. Li SH, et al. Trends Genet. 2004 Mar;20(3):146-54. doi: 10.1016/j.tig.2004.01.008. Trends Genet. 2004. PMID: 15036808 Review. - The spinocerebellar ataxia type 1 protein, ataxin-1, has RNA-binding activity that is inversely affected by the length of its polyglutamine tract.
Yue S, Serra HG, Zoghbi HY, Orr HT. Yue S, et al. Hum Mol Genet. 2001 Jan 1;10(1):25-30. doi: 10.1093/hmg/10.1.25. Hum Mol Genet. 2001. PMID: 11136710
Cited by
- Why Is Arginine the Only Amino Acid That Inhibits Polyglutamine Monomers from Taking on Toxic Conformations?
Tanimoto S, Okumura H. Tanimoto S, et al. ACS Chem Neurosci. 2024 Aug 7;15(15):2925-2935. doi: 10.1021/acschemneuro.4c00276. Epub 2024 Jul 15. ACS Chem Neurosci. 2024. PMID: 39009034 Free PMC article. - Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.
Tenchov R, Sasso JM, Zhou QA. Tenchov R, et al. ACS Chem Neurosci. 2024 Aug 7;15(15):2665-2694. doi: 10.1021/acschemneuro.4c00184. Epub 2024 Jul 12. ACS Chem Neurosci. 2024. PMID: 38996083 Free PMC article. Review. - Postmortem neuropathology in early Huntington disease.
Hedreen JC, Berretta S, White Iii CL. Hedreen JC, et al. J Neuropathol Exp Neurol. 2024 Apr 19;83(5):294-306. doi: 10.1093/jnen/nlae022. J Neuropathol Exp Neurol. 2024. PMID: 38553027 Free PMC article. - Huntington disease-like 2: insight into neurodegeneration from an African disease.
Krause A, Anderson DG, Ferreira-Correia A, Dawson J, Baine-Savanhu F, Li PP, Margolis RL. Krause A, et al. Nat Rev Neurol. 2024 Jan;20(1):36-49. doi: 10.1038/s41582-023-00906-y. Epub 2023 Dec 19. Nat Rev Neurol. 2024. PMID: 38114648 Review. - Repressor Element-1 Binding Transcription Factor (REST) as a Possible Epigenetic Regulator of Neurodegeneration and MicroRNA-Based Therapeutic Strategies.
Nassar A, Satarker S, Gurram PC, Upadhya D, Fayaz SM, Nampoothiri M. Nassar A, et al. Mol Neurobiol. 2023 Oct;60(10):5557-5577. doi: 10.1007/s12035-023-03437-1. Epub 2023 Jun 16. Mol Neurobiol. 2023. PMID: 37326903 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials